Piper Sandler Reiterates Overweight on Tempest Therapeutics, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Edward Tenthoff has reiterated an Overweight rating on Tempest Therapeutics (NASDAQ:TPST) and maintained a price target of $8.

June 21, 2024 | 5:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler analyst Edward Tenthoff has reiterated an Overweight rating on Tempest Therapeutics (NASDAQ:TPST) and maintained a price target of $8.
The reiteration of an Overweight rating and the maintenance of a price target at $8 by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100